Abstract <p>N6-methyladenosine (m⁶A) is the most abundant internal RNA modification in eukaryotic mRNAs and plays a crucial role in regulating mRNA stability, translation, and degradation. Dysregulation of m⁶A regulators has been increasingly implicated in cancer, yet their cell type–specific roles and therapeutic value in ovarian cancer remain clearly unexplored. We conducted an integrative analysis of single-cell and bulk RNA sequencing datasets from ovarian tumors and matched non-malignant tissues to identify m⁶A regulators associated with tumor progression. Functional experiments, including gene knockdown, flow cytometry, metabolic assays, and RIP-seq analysis, were performed to evaluate the role of candidate regulators. A small-molecule inhibitor of IGF2BP2 (CWI1-2) was also used to assess therapeutic potential in ovarian cancer cell lines. IGF2BP2 was identified as the most significantly upregulated m⁶A reader in malignant epithelial cells and was associated with poor patient prognosis. Knockdown of IGF2BP2 impaired cell proliferation, induced cell cycle arrest and apoptosis, and suppressed glycolytic activity. RIP-seq data revealed that IGF2BP2 directly binds transcripts of key oncogenes including CDK4, BCL2L2, and SLC2A1, thereby stabilizing their expression. Pharmacological inhibition of IGF2BP2 recapitulated the effects of genetic silencing, confirming its essential role in sustaining oncogenic programs in ovarian cancer cells. Our findings establish IGF2BP2 as a critical m⁶A reader that post-transcriptionally regulates gene networks driving proliferation, survival, and metabolic reprogramming in ovarian cancer. Targeting IGF2BP2 may represent a promising therapeutic strategy for m⁶A-based precision oncology in ovarian cancer.</p>